Name | Value |
---|---|
Revenues | 394.1M |
Cost of Revenue | 138.3M |
Gross Profit | 255.8M |
Operating Expense | 153.1M |
Operating I/L | 102.6M |
Other Income/Expense | -18.3M |
Interest Income | 8.9M |
Pretax | 84.4M |
Income Tax Expense | 22.3M |
Net Income/Loss | 62.1M |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases globally. Its product portfolio includes microbubble ultrasound enhancing agents, technetium generators, radiotherapeutics, imaging agents, and AI-based medical device software. The company also offers investigational products such as PSMA-targeted small molecules and humanized monoclonal antibodies. Lantheus serves a wide range of healthcare providers and has strategic partnerships with leading companies in the industry. Its revenue is generated through the sale of diagnostic and therapeutic products, as well as through collaborations and partnerships.